Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Ref… (NCT05059782) | Clinical Trial Compass
UnknownNot Applicable
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
China150 participantsStarted 2021-10-10
Plain-language summary
In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18;
✓. Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
✓. Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3;
✓. No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency
✓. Good compliance, signed informed consent voluntarily.
Exclusion criteria
✕. Previous radiotherapy at the target lesion site;
✕. History of active inflammatory bowel disease or severe stomach and duodenal ulcers;
✕. Human immunodeficiency virus (HIV) infected persons;
✕. active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit);
✕. suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication: